title: Clinical and economic assessment of the omeprazole test in patients with symptoms suggestive of gastroesophageal reflux disease.
abstract: OBJECTIVE
  To evaluate the diagnostic accuracy of a trial of a high-dose proton pump inhibitor (the omeprazole test) in detecting gastroesophageal reflux disease (GERD) in patients with heartburn symptoms.
  
  
  METHODS
  A randomized, double-blind, placebo-controlled, crossover trial.
  
  
  METHODS
  Forty-three consecutive patients with symptoms suggestive of GERD were enrolled at a Veterans Affairs medical center.
  
  
  METHODS
  Symptom response to the omeprazole test vs placebo in GERD-positive and GERD-negative patients; sensitivity, specificity, and positive and negative predictive values of the omeprazole test; and cost per correct diagnosis achieved with the omeprazole test compared with traditional diagnostic strategies.
  
  
  RESULTS
  Of 42 patients (98%) who completed the study, 35 (83%) were classified as GERD positive and 7 (17%) as GERD negative. Twenty-eight GERD-positive and 3 GERD-negative patients responded to the omeprazole test, providing a sensitivity of 80.0% (95% confidence interval, 66.7%-93.3%) and a specificity of 57.1% (95% confidence interval, 20.5%-93.8%). Economic analysis revealed that the omeprazole test saves $348 per average patient evaluated, and results in a 64% reduction in the number of upper endoscopies performed and a 53% reduction in the use of pH testing.
  
  
  CONCLUSIONS
  The omeprazole test is sensitive and fairly specific for diagnosing GERD in patients with typical GERD symptoms. This strategy could result in significant cost savings and decreased use of invasive diagnostic tests.
authors.affiliation: Department of Medicine, Tucson Veterans Affairs Medical Center and Arizona Health Sciences Center, 85723, USA. ronnie.fass@med.va.gov
authors.forename: R
authors.initials: R
authors.lastname: Fass
authors.forename: J J
authors.initials: JJ
authors.lastname: Ofman
authors.forename: I M
authors.initials: IM
authors.lastname: Gralnek
authors.forename: C
authors.initials: C
authors.lastname: Johnson
authors.forename: E
authors.initials: E
authors.lastname: Camargo
authors.forename: R E
authors.initials: RE
authors.lastname: Sampliner
authors.forename: M B
authors.initials: MB
authors.lastname: Fennerty
mesh_terms: D000328:Adult; D000368:Aged; D000897:Anti-Ulcer Agents / Q000191:economics*; D001130:Arizona; D003362:Cost-Benefit Analysis; D018592:Cross-Over Studies; D003937:Diagnosis, Differential; D004311:Double-Blind Method; D004947:Esophagus / Q000503:physiopathology; D005260:Female; D005764:Gastroesophageal Reflux / Q000175:diagnosis* / Q000191:economics* / Q000503:physiopathology; D006787:Hospitals, Veterans; D006801:Humans; D006863:Hydrogen-Ion Concentration; D008297:Male; D008875:Middle Aged; D008991:Monitoring, Physiologic; D009853:Omeprazole / Q000191:economics*; D011237:Predictive Value of Tests; D012680:Sensitivity and Specificity
chemical_list: D000897:Anti-Ulcer Agents; D009853:Omeprazole